Outset Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.5%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$125.7Mnext fiscal year
FY EPS (est.)
-$2.91next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Net Revenue Quarterly27.9MTarget: 125000000 to 130000000
Recurring Revenue (Consumables and Service) Quarterly22.5M
GAAP Gross Margin Quarterly4,340.0%Target: Low-to-mid 40% range (Non-GAAP)
Product Gross Margin Quarterly5,240.0%
Watch Items
- FDA 510(k) clearance and commercial shipment of next-generation Tablo platformTrigger: Shipment commencement in Q2 2026Action: Monitor quarterly product revenue growth and capital sales pipeline conversion.
- Cash burn rate and path to cash flow breakevenTrigger: Cash balance falling below $120 millionAction: Evaluate operational expense discipline and working capital efficiency.
Research as of 19 Jun 2026